Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) saw unusually-strong trading volume on Tuesday . Approximately 184,418 shares traded hands during mid-day trading, an increase of 29% from the previous session’s volume of 143,326 shares.The stock last traded at $8.47 and had previously closed at $8.35.

A number of equities analysts have weighed in on ADAP shares. Zacks Investment Research cut Adaptimmune Therapeutics PLC – from a “buy” rating to a “hold” rating in a report on Monday. Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $15.94.

The stock’s 50-day moving average price is $8.42 and its 200 day moving average price is $8.64. The firm’s market cap is $616.54 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. On average, equities research analysts anticipate that Adaptimmune Therapeutics PLC – will post ($1.12) earnings per share for the current year.

In other news, Director Orbimed Advisors Llc acquired 1,712,400 shares of the firm’s stock in a transaction dated Tuesday, May 24th. The shares were bought at an average price of $10.42 per share, with a total value of $17,843,208.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Charles Elliott Sigal acquired 45,000 shares of the firm’s stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $68,850.00. Following the acquisition, the director now directly owns 52,938 shares in the company, valued at approximately $80,995.14. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Adaptimmune Therapeutics PLC – stock. Jennison Associates LLC boosted its stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 0.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 486,948 shares of the company’s stock after buying an additional 1,547 shares during the period. Jennison Associates LLC owned 0.69% of Adaptimmune Therapeutics PLC – worth $5,873,000 at the end of the most recent quarter.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.